Integrated Drug Discovery

From target validation to pre-clinical candidate selection, Jubilant Biosys offers comprehensive integrated drug discovery solutions.

Read More

Services

Download Brochure Request
Integrated Drug Discovery

Pioneering Excellence in Integrated Drug Discovery

Jubilant Biosys offers a comprehensive, streamlined and integrated drug discovery process designed to achieve rapid milestones in the discovery of novel therapeutics. Our services under Integrated Drug Discovery span Target Validation (TV), Hit Identification (HI) to Lead Optimization (LO) and Pre-Clinical Candidate Selection (PCC) across multiple therapeutic areas including but not limited to oncology, CNS, metabolic disorders, pain & inflammation.

With well enabled capabilities in oncology, metabolic disorders, CNS, pain and inflammation Jubilant, as an integrated discovery service provider has rapidly emerged as a leading collaborator for biotechnology and pharmaceutical companies worldwide.

Jubilant’s expertise in discovery informatics, computational chemistry / molecular modelling, medicinal chemistry, structural biology, in-vitro pharmacology, DMPK, in-vivo pharmacology and toxicology span over 20 years of successful delivery in first in class and best in class targets.

We have expertise in multiple target classes including kinases/non-kinases, enzymes & non-enzymes, GPCRs, orphan receptors, transporters and others. We strive to leverage advanced technologies and expertise to foster speedy execution and deliver promising drug candidates.

Jubilant Drug Discovery at a Glance

  • 400+ people working on drug discovery at Bangalore.
  • Demonstrated expertise: ~85 programs successfully delivered across multiple therapeutic areas.

Oncology

30+ Programs

Metabolic Disorder

15+ Programs

CNS

15+ Programs

Pain & Inflammation (P&I)

20+ Programs

Integrated Drug Discovery Services

Pre-Clinical Workflow

A Customized Approach

Jubilant operates on a customized approach offering innovative solutions across the drug discovery value chain to the biotechnology and pharmaceutical industry. To suit each client’s requirements in the best possible manner, we offer flexibility through the following business models:

  • Integrated Drug Discovery Programs
  • Milestone and Hybrid Models
  • Full Time Equivalent (FTE) based
  • Fee For Service (FFS) based

Jubilant collaborates with the world’s leading pharmaceutical and biotech companies, academic institutions and research foundations. Innovative and rigorous science, excellence in execution, and absolute integrity, combined with flexible business models has enabled Jubilant to deliver valuable outcomes in a relatively short period of time. The hallmark of Jubilant’s collaborative model is the creation of value to partners.

Accelerating Drug Discovery: From Target/Hit Identification to Candidate
Identification / Selection

At the heart of pharmaceutical innovation lies the drug discovery process, which encompasses meticulous scientific exploration, including the pivotal early stages of research – from Target/Hit Identification and validation to the identification of a drug candidate or lead compound.

At Jubilant Biosys, we are at the forefront of this exciting journey and offer integrated drug discovery services that combine advanced technologies, expert teams, and efficient workflows.

Various stages of Integrated Drug Discovery

Integrated

Drug Discovery

Workflow

Integrated Drug Discovery (IDD) SolutionsOffered by Jubilant Biosys

Target to Lead Generation
  • Protein production, Crystallography, SPR platform for screening
  • Fragment identification and Screening
  • Medicinal & Computational Chemistry approaches
  • In-vitro Screening and Profiling
  • Early ADMET & PK
  • In-vivo Pharmacology
Lead Optimisation
  • Medicinal Chemistry
  • DMPK
  • SBDD (Co-crystallisation, Computational Modelling)
  • Target Engagement & Disease Models, Safety Profile
  • Pre-formulation
Candidate Selection (IND)
  • Process Development (Including Flow Chemistry), Scale-up & GMP API Supply
  • Genotox (Non-GLP & GLP Toxicology)
  • D2M Predictions (WinNonlin)
API Custom Scale up
  • GMP API scale- up to MT
  • OEB Class 1-3 API Potency

Why Jubilant for Integrated Drug Discovery?

  • Successfully delivered 85+ IDD programs across multiple therapeutic areas.
  • Preferred collaborator for biotech & pharma companies worldwide for the past two decades.
  • Experienced team comprising scientific professionals, with Masters to PhD ratio of 6:1.
  • PhDs with overseas exposure, having worked at premier institutions and organisations.
  • Seamless, integrated approach to drug discovery.
  • Medicinal chemistry expertise across multiple therapeutic areas and intervention strategies.
  • De-novo assay development & validation capabilities; screening support and in vivo model development and validation.
  • Timely ADMET support.
  • Updated technologies & customised approach for developing innovative solutions.
  • Best practices in documentation.
  • Reliable quality solutions & & ISO 9001:2015, ISO14001:2015, ISO45001:2018 certified.
  • End-to-end CRDMO solutions beyond IDD.
Get In Touch